PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Higher Net Receivables Growth compared to AGEN's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Above 1.5x AGEN's -30.67%. Michael Burry might investigate for potential short-term asset misclassification or risk.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
≥ 1.5x AGEN's -13.31%. David Dodd sees more aggressive capex. Confirm it's not overspending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
≥ 1.5x AGEN's -7.05%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
100.00%
Higher Other Assets Growth compared to AGEN's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-99.84%
Above 1.5x AGEN's -57.86%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
-100.00%
Less than half of AGEN's 2.71%. David Dodd sees much smaller short-term leverage burden vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Below half of AGEN's -0.53%. Michael Burry suspects a big gap in pre-sales traction.
100.00%
Less than half of AGEN's -26.15%. David Dodd sees fewer expansions in other current obligations.
13.77%
Similar yoy to AGEN's 15.87%. Walter Schloss sees parallel short-term liability strategies.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.32%
Above 1.5x AGEN's 6.81%. Michael Burry sees a strong spike vs. competitor. Check coverage and debt ratios.
No Data
No Data available this quarter, please select a different quarter.
11.40%
1.25-1.5x AGEN's 7.87%. Martin Whitman is wary of bigger liability expansions.
No Data
No Data available this quarter, please select a different quarter.
-3.71%
Below half AGEN's 1.11%. Michael Burry suspects major net losses or high dividends vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
110.36%
Above 1.5x AGEN's 50.79%. Michael Burry suspects a significant bump in 'other' equity items vs. competitor.
-11.42%
Below half AGEN's 38.62%. Michael Burry sees potential underperformance in building shareholder capital.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.32%
Above 1.5x AGEN's 1.16%. Michael Burry sees a major jump. Investigate leverage rationale.
10.35%
Less than half of AGEN's -60.68%. David Dodd sees better deleveraging or stronger cash buildup than competitor.